Project Grant R33CA309703
Award Date 3/13/26
Completion Date 2/28/29
Dollars Obligated $431K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- Federal Project Grant Award Summary Beth Israel Deaconess Medical Center, Inc. (BIDMC) received a $846,982 Project Grant from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) effective August 1, 2025, through July 31, 2032. The research project, "Navigating Pathways of Innate Immunity and Epigenetic Memory in Checkpoint Immunotherapy," focuses on elucidating how the PD-1 receptor and associated signaling pathways regulate hematopoietic stem and progenitor...
- Federal Grant Award Summary Beth Israel Deaconess Medical Center, Inc. received a $818,625 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded September 1, 2025, with an ultimate completion date of August 31, 2030. The project will conduct a randomized controlled trial evaluating cardioprotective strategies in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients with pre-existing cardiomyopathy or prior anthracycline...
- Federal Project Grant Award Summary Beth Israel Deaconess Medical Center, Inc. (BIDMC) received a $470,567 Project Grant (R21) award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on July 15, 2025, with an ultimate completion date of June 30, 2027. The award funds research to identify molecular features that predict response or resistance to poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor therapy in metastatic breast cancer patients...
- Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research a $418,176 Project Grant under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This award supports the continued advanced development and validation of programmable nucleic acid cytometry technology, specifically building upon the Institute's prior work with Programmable Enrichment via RNA Fluorescence In Situ Hybridization...
- Federal Grant Award Summary Grant Details: Boston Children's Hospital received a $679,604 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded August 1, 2025, with completion scheduled for July 31, 2030. Products and Services: This research project delivers fundamental cancer biology research focused on understanding melanoma initiation pathways using a zebrafish model system. The research employs advanced cellular and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $443,564 Project Grant to The Broad Institute of MIT and Harvard on September 2, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop an innovative cancer immunotherapy platform using engineered commensal skin bacteria. The award funds research through August 31, 2027, and supports the development of methods to express defined tumor antigens in diverse skin commensal bacteria species and evaluate...
- Federal Grant Award Summary The National Cancer Institute awarded a $176,040 Project Grant to Massachusetts General Hospital under the Cancer Research Manpower program (CFDA 93.398) effective July 1, 2025 through June 30, 2027. The award funds research to develop engineered CAR-T (Chimeric Antigen Receptor T) cell therapies capable of overcoming the cancer cell glycocalyx barrier, a protective layer that impedes immune cell recognition and destruction of solid tumors. The research addresses a...
- Federal Project Grant Award Summary Beth Israel Deaconess Medical Center, Inc. received a $169,884 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective July 1, 2025 through June 30, 2027. The award funds biomedical research training and investigator-led research focused on elucidating molecular mechanisms underlying small cell lung cancer (SCLC) pathogenesis and identifying novel therapeutic targets. Specifically, the research...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The National Cancer Institute awarded a $736,168 Project Grant to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) for the period of August 1, 2025, through July 31, 2030. The research focuses on developing antigen-specific radiosensitization through antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs) designed to enhance the therapeutic index of radiotherapy. The project centers on two...